MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Market Cap 2011-2026 | DRRX
As of March 05, 2026 DURECT Corporation has a market cap of $ 50.1 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.8 M | 110 M | 14.9 M | 44.3 M | 345 M | 97.5 M | 174 M | 142 M | 142 M | 105 M | 226 M | 92.9 M | 69.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 M | 14.9 M | 123 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Cronos Group
CRON
|
3.63 B | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
4.54 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
271 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
Assertio Holdings
ASRT
|
66.1 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
35.5 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
162 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
226 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
23.9 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 7.33 | -0.48 % | $ 4.53 B | Canada |
 |
Veru
VERU
|
108 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |